Log in

OTCMKTS:NWPHF - Newron Pharmaceuticals Stock Price, Forecast & News

0.00 (0.00 %)
(As of 11/27/2019)
Today's Range
Now: $7.50
50-Day Range
MA: $7.89
52-Week Range
Now: $7.50
Volume150 shs
Average Volume68 shs
Market Capitalization$133.80 million
P/E RatioN/A
Dividend YieldN/A
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$4.75 million
Book Value$3.63 per share



Market Cap$133.80 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NWPHF News and Ratings via Email

Sign-up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter.

Newron Pharmaceuticals (OTCMKTS:NWPHF) Frequently Asked Questions

What is Newron Pharmaceuticals' stock symbol?

Newron Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NWPHF."

Has Newron Pharmaceuticals been receiving favorable news coverage?

Press coverage about NWPHF stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Newron Pharmaceuticals earned a news impact score of 1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Newron Pharmaceuticals.

Who are some of Newron Pharmaceuticals' key competitors?

What other stocks do shareholders of Newron Pharmaceuticals own?

Who are Newron Pharmaceuticals' key executives?

Newron Pharmaceuticals' management team includes the folowing people:
  • Mr. Stefan Weber, CEO & Exec. Director (Age 54)
  • Mr. Roberto Galli, VP of Fin.
  • Mr. Marco Caremi, Exec. VP of Bus. Devel. (Age 62)
  • Dr. Ravi Anand, Chief Medical Officer (Age 62)
  • Mr. Dennis Dionne, VP of Commercial Affairs (Age 69)

How do I buy shares of Newron Pharmaceuticals?

Shares of NWPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Newron Pharmaceuticals' stock price today?

One share of NWPHF stock can currently be purchased for approximately $7.50.

How big of a company is Newron Pharmaceuticals?

Newron Pharmaceuticals has a market capitalization of $133.80 million and generates $4.75 million in revenue each year. The company earns $-17,760,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Newron Pharmaceuticals employs 24 workers across the globe.View Additional Information About Newron Pharmaceuticals.

What is Newron Pharmaceuticals' official website?

The official website for Newron Pharmaceuticals is http://www.newron.com/.

How can I contact Newron Pharmaceuticals?

Newron Pharmaceuticals' mailing address is Via Ludovico Ariosto 21, Bresso Mi, 20091. The company can be reached via phone at 39-02-6103-4630 or via email at [email protected]

MarketBeat Community Rating for Newron Pharmaceuticals (OTCMKTS NWPHF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  164
MarketBeat's community ratings are surveys of what our community members think about Newron Pharmaceuticals and other stocks. Vote "Outperform" if you believe NWPHF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWPHF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel